San Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases, today announced that its Chief Executive Officer, Patrice Rioux, MD, Ph.D., will participate as a panelist in the United Mitochondrial Disease Foundation's ("UMDF") 2026 Bench-to-Bedside webinar on January 5, 2026.During th ...

As of Dec. 30, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzin ...

As of Dec. 30, 2025, two stocks in the energy sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzin ...

Core Insights - TETRA Technologies, Inc. has signed a term sheet to form a joint venture with Magrathea Metals, Inc. to enhance the domestic magnesium metal supply chain in the U.S. [1][4] - Magnesium is recognized as a critical mineral essential for the defense industrial base and broader economy [2][6] Group 1: Joint Venture and Strategic Goals - The joint venture aims to rebuild America's magnesium metal defense industrial base at TETRA's Evergreen Project in Southwest Arkansas [1][4] - TETRA's ONE TETRA 2030 strategy focuses on clean and secure domestic manufacturing of critical minerals, including magnesium [4] - Magrathea has received Defense Production Act Title III funding to support its initial commercial phase at TETRA's Evergreen Plant [4] Group 2: Project Details - TETRA is constructing a bromine production facility projected to produce 75 million lbs. of bromine annually, with operations expected to start by the end of 2027 [3] - The Evergreen Project will also focus on producing lithium and magnesium from brine, leveraging Magrathea's innovative electrolytic magnesium technology [3][4] Group 3: Industry Context - The partnership is positioned to enhance the U.S. supply chain for magnesium, which is critical for national security and economic stability [2][6] - The collaboration is seen as a significant step towards ensuring that the U.S. can compete globally in the defense industry [4]

Group 1 - TETRA Technologies, Inc. will host one-on-one meetings with institutional investors on December 10, 2025, at the Wells Fargo 24th Annual Energy & Power Symposium in New York City [1] - The company focuses on environmentally conscious services and solutions across six continents, with a portfolio that includes Energy Services, Industrial Chemicals, and Critical Minerals [2] - TETRA is expanding into the low-carbon energy market, leveraging its chemistry expertise and global infrastructure to meet the demand for sustainable energy [2] Group 2 - TETRA Technologies announced strong third quarter 2025 financial results, indicating positive performance [4] - The company is undergoing a CFO transition with the planned retirement of Elijio Serrano and the appointment of Matt Sanderson [5]

Core Insights - Thiogenesis Therapeutics plans to initiate a Phase 3 pivotal clinical trial for TTI-0102, targeting nephropathic cystinosis, with an Investigational New Drug (IND) application expected in early 2026 [1][10] Group 1: Company Overview - Thiogenesis Therapeutics is a clinical-stage biotechnology company focused on developing sulfur-based prodrugs for rare mitochondrial and metabolic diseases [10] - The company is publicly traded on the TSX Venture Exchange and OTCQX, with operations based in San Diego, California [10] Group 2: Product Details - TTI-0102 is a next-generation cysteamine-based prodrug designed to improve tolerability and simplify dosing compared to existing therapies [3][4] - The drug consists of two cysteamine molecules and one molecule of pantothenic acid (Vitamin B5), allowing for once-daily dosing with reduced peak-related toxicity [9] Group 3: Clinical Trial Insights - The Phase 3 trial will utilize established endpoints and trial design informed by biomarker and tolerability data from the ongoing MELAS clinical study [5][7] - The trial aims to address limitations of current cysteamine therapies, which require multiple daily doses and are associated with significant side effects [2][13] Group 4: Market Opportunity - The global population of cystinosis patients exceeds 2,000, representing a market opportunity of over $300 million [2]

Core Insights - Thiogenesis Therapeutics reported positive interim results from its Phase 2 clinical trial of TTI-0102 for MELAS, achieving biological proof-of-concept, dose discovery, and biomarker improvement [1][2][5] MELAS Clinical Trial - The Phase 2 trial included nine patients, with six receiving TTI-0102 and three on placebo, focusing on biological proof-of-concept, dose discovery, and early efficacy [2] - Five active patients remain in the trial, with TTI-0102 well tolerated, although four patients under 50 kg left due to dose-dependent side effects, indicating a need for refined dosing protocols [3] - The interim analysis showed significant support for TTI-0102's mitochondrial antioxidant and restorative activity, with individual biomarker data remaining confidential until early 2026 [4] Future Plans and Pipeline Updates - The company anticipates final 6-month data from the MELAS cohort by January 2026 and plans to file an Investigational Medicinal Product Dossier (IMPD) to initiate a pivotal Phase 3 trial in Europe in 2026 [6][7] - For Leigh syndrome spectrum, the FDA accepted the IND application, with a Phase 2 trial expected to start in early 2026, incorporating dosing adjustments based on MELAS interim data [8] - The company plans to file an IND application for a Phase 3 trial in nephropathic cystinosis, comparing TTI-0102 to current cysteamine therapies, which have significant side effects [9][10] About TTI-0102 - TTI-0102 is a disulfide compound designed to overcome limitations of existing thiol-based drugs, offering potential for once-daily dosing and improved tolerability [15] - The compound targets mitochondrial dysfunction, with applications in MELAS and other pediatric diseases [16]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Financial Data and Key Metrics Changes - The company achieved record revenue of $484 million and adjusted EBITDA of $93 million over the past 10 years, with Q3 revenue at $153 million and adjusted EBITDA at $25 million, reflecting an 8% year-over-year increase in revenue and a 7% rise in adjusted EBITDA [6][7][19] - Adjusted EBITDA margins for Q3 were 16%, with completion fluids and products revenues increasing 39% year-over-year [7][8] - The company ended Q3 with $67 million in cash and a net leverage ratio of 1.2 times, with working capital at $113 million, only a $4 million increase from year-end [17][18] Business Line Data and Key Metrics Changes - Completion fluids and products saw a significant revenue increase, with adjusted EBITDA margins reaching 34.5%, a 500 basis point improvement compared to the same period in 2024 [8][9] - Water and flowback services revenue declined 2% sequentially and 18% year-over-year, but adjusted EBITDA rose 18% sequentially due to better cost controls [9][10] - The industrial calcium chloride business continues to perform well, with record quarters and expansion into new applications [48][49] Market Data and Key Metrics Changes - The deepwater rig count is currently 40% lower than it was 10 years ago, yet the company has achieved significant market penetration [6][7] - The company is experiencing increased unconventional activity in Argentina and the Middle East, with 100% utilization of automated SandStorm units in Argentina [10][11] - The outlook for the completion fluids and products business remains strong, driven by deepwater completion activity and increased demand for battery electrolyte revenue [9][12] Company Strategy and Development Direction - The company unveiled its "One TETRA 2030" strategy, aiming to leverage its core fluids chemistry expertise into high-growth markets, including battery electrolytes and produced water desalination solutions [12][13] - The goal is to more than double revenue to over $1.2 billion and triple adjusted EBITDA to over $300 million by 2030 [13][16] - The company is focused on generating over $100 million in annual adjusted free cash flow by 2030, driving meaningful cash returns to shareholders [16] Management's Comments on Operating Environment and Future Outlook - Management expressed strong conviction in the long-term outlook despite macroeconomic and energy market uncertainties, highlighting the company's ability to differentiate in its markets [23][62] - The company anticipates continued offshore activity growth, particularly in the Gulf of America, Brazil, and North Sea, with confidence in executing TETRA Neptune projects in 2026 [31][55] - The company is optimistic about the desalination market, expecting to sign its first commercial contract in the coming quarters [15][44] Other Important Information - Elijio Serrano, the CFO, announced his retirement at the end of March 2026, with Matthew Sanderson set to replace him [4][5] - The company is relocating to a new corporate office, expecting to reduce lease expenses by approximately $2 million per year [18][19] Q&A Session Summary Question: Update on Oasis Commercial Engineering and next steps - The FEED study has been completed, and discussions with customers are ongoing to socialize the economics and financials [25][26] Question: Factors behind sequential decline in CFP sales - The decline was primarily due to seasonal industrial calcium chloride sales and the absence of Neptune jobs, partially offset by increased activity in Brazil [27][28] Question: Confidence in offshore market for 2026 and 2027 - Management expressed strong confidence in the deepwater market's growth, with a robust pipeline for TETRA Neptune projects [31][32] Question: Update on desalination projects and capital costs - The core technology will remain owned by TETRA, with various commercial models being considered, and capital costs are estimated at $1 million per 1,000 barrels of desalination [33][34] Question: Outlook for 2026 compared to 2025 - The company expects significant growth in Argentina and the Middle East, with a strong outlook for deepwater projects [36][38] Question: Opportunities in Saudi Arabia and Sandstorm - The company sees potential for growth in Saudi Arabia, similar to the success experienced in Argentina [58][59]

Company Overview - TETRA's market capitalization is $105 billion as of October 24, 2025[14] - The company's net debt is $114 million as of September 30, 2025[14] - The enterprise value is $117 billion as of October 24, 2025[14] - Q3 2025 TTM revenue is $619 million, with an adjusted EBITDA margin of 187%[15,21] Financial Performance and Targets - 2024 revenue was $599 million, with adjusted EBITDA of $994 million[20] - 2025 revenue guidance is $620-630 million, with adjusted EBITDA of $107-112 million[20] - The company targets 2030 revenue of $125 billion, representing a 15% CAGR, and adjusted EBITDA of $325 million, with a 26% adjusted EBITDA margin[146] Business Segments and Growth - Completion Fluids & Products revenue is $362 million TTM, with an adjusted EBITDA margin of 331%[15,41] - Water & Flowback Services revenue is $257 million TTM, with an adjusted EBITDA margin of 121%[15] - The company is transitioning to three future segments: Energy Services, Specialty Chemicals & Minerals, and Water Treatment & Desalination[27] Critical Minerals and Bromine Project - TETRA has over 40000 acres of mineral-rich Smackover brine leases[115] - The Arkansas Bromine Project has a projected incremental revenue of $230 million and incremental EBITDA of $105 million at full production[124] - The Arkansas Bromine Project has a project capex of $270 million, an NPV10 of $710 million, and an IRR of 62%[124]